Rein Therapeutics Competitors and Similar CompaniesClear all

Rein Therapeutics's competitors and similar companies include Seagen, iBio, Century Therapeutics and Gliknik.

	Rein Therapeutics Rein Therapeutics (formerly known as Aileron Therapeutics) is a clinical-stage biopharmaceutical company that develops medicines targeting undruggable cancer sites using its proprietary platform of stabilized cell-permeating peptides.	Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer.	iBio iBio is a biotechnology research company.	Century Therapeutics Century Therapeutics is a biotech company that develops therapies to treat cancer.	Gliknik Gliknik is a biopharmaceutical company creating therapies for people living with cancer and immune disorders.
Founding Date	Founding Date 2005	Founding Date 1998	Founding Date 2008	Founding Date 2018	Founding Date 2007
Type	Type Public	Type Subsidiary	Type Public	Type Public	Type Private
Tags	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy
Locations	Locations Watertown, US HQ Boston, US	Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more	Locations San Diego, US HQ Bryan, US	Locations Philadelphia, US HQ Hamilton, CA Seattle, US	Locations Baltimore, US HQ
Employees	Employees 838% decrease	Employees 3,25622% increase	Employees 1630% decrease	Employees 107	Employees 9
Valuation ($)	Valuation ($) 90.2 m	Valuation ($) N/A	Valuation ($) 26.2 m	Valuation ($) 115.2 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $2b (FY, 2022)	Revenue (est.) $400k (FY, 2025)	Revenue (est.) $109.2m (FY, 2025)	Revenue (est.) N/A
Net income	Net income ($49.9m) (FY, 2025)	Net income ($610.3m) (FY, 2022)	Net income N/A	Net income ($9.6m) (FY, 2025)	Net income N/A
Operating ⚠
Patents Issued	Patents Issued 175 (May, 2017)	Patents Issued N/A	Patents Issued 67 (FY, 2016)	Patents Issued N/A	Patents Issued N/A
Patents Pending	Patents Pending 205 (May, 2017)	Patents Pending N/A	Patents Pending 19 (FY, 2016)	Patents Pending N/A	Patents Pending N/A
Funding
Total funding raised	Total funding raised $ 112m	Total funding raised $ 164m	Total funding raised $ 9.3m	Total funding raised $ 410m	Total funding raised $ 65.1m